Moreover, research should encompass longitudinal analyses of GIMAP1-GIMAP5 expression in patients with lung adenocarcinoma, both prior to and following COVID-19 infection, to establish whether the alterations in expression are a consequence of the virus's direct effects or are induced by the immune response it triggers. This evidence concerns the gene GIMAP5 and lung adenocarcinoma.